• Angelini Pharma agreed to buy Catalyst Pharmaceuticals for USD 31.5 per share in cash, valuing equity at about USD 4.1 billion.
• Price implies 21% premium to unaffected close on April 22, 2026, before signs of deal talks surfaced.
• Closing targeted for Q3 2026.
• Deal gives Angelini an entry point into U.S. market, adding Catalyst rare-disease portfolio and commercial infrastructure to its brain-health focus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070214PRIMZONEFULLFEED1001180497) on May 07, 2026, and is solely responsible for the information contained therein.